SFM
BBIO icon

Sphera Funds Management’s BridgeBio Pharma BBIO Stock Holding History

Sphera Funds Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18.3M Buy
245,346
+100
+0% +$7K 2.38% 11
2026
Q1 		$18.2M Buy
245,246
+137,500
+128% +$9.97M 2.89% 6
2025
Q4 		$8.24M Buy
107,746
+67,000
+164% +$4.4M 1.59% 16
2025
Q3 		$2.12M Sell
40,746
-46,362
-53% -$2.26M 0.45% 72
2025
Q2 		$3.76M Sell
87,108
-279,500
-76% -$10.2M 0.88% 42
2025
Q1 		$12.7M Sell
366,608
-538,671
-60% -$18.2M 2.92% 7
2024
Q4 		$24.8M Buy
905,279
+62,635
+7% +$1.62M 4.49% 2
2024
Q3 		$21.5M Sell
842,644
-67,426
-7% -$1.77M 3.41% 3
2024
Q2 		$23.1M Buy
910,070
+324,114
+55% +$8.86M 3.14% 3
2024
Q1 		$18.1M Buy
585,956
+303,810
+108% +$10.3M 2.55% 8
2023
Q4 		$11.4M Sell
282,146
-63,391
-18% -$1.9M 1.83% 16
2023
Q3 		$9.11M Buy
345,537
+23,902
+7% +$678K 1.66% 14
2023
Q2 		$5.53M Sell
321,635
-240,348
-43% -$3.62M 0.86% 46
2023
Q1 		$9.32M Buy
+561,983
New +$6.55M 1.56% 19
2021
Q2 		– Sell
-23,890
Closed -$1.47M – 136
2021
Q1 		$1.47M Sell
23,890
-134,010
-85% -$8.77M 0.11% 131
2020
Q4 		$11.2M Buy
+157,900
New +$7.62M 1% 27

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Sphera Funds Management's BBIO Position: Q2 2026 in Review

Sphera Funds Management increased its BridgeBio Pharma (BBIO) stake by 0.04% in Q2 2026, buying an estimated $7K and bringing the position to 245,346 shares worth $18.3M. The position accounts for 2.38% of the portfolio, ranked #11.

Sphera Funds Management first reported a position in BBIO in Q4 2020 and has held it in 16 quarters since. The position peaked at $24.8M in Q4 2024. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Sphera Funds Management held 245,346 shares of BridgeBio Pharma worth $18.3M as of Q2 2026.
  • Sphera Funds Management bought 100 BridgeBio Pharma shares in Q2 2026, an estimated $7K.
  • BridgeBio Pharma made up 2.38% of Sphera Funds Management's portfolio in Q2 2026, its #11 holding.
  • Sphera Funds Management first reported a position in BridgeBio Pharma in Q4 2020 and has held it in 16 quarters since.
  • Sphera Funds Management's BridgeBio Pharma position peaked at $24.8M in Q4 2024.
  • 475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Sphera Funds Management's 13F filing for Q2 2026, filed 14 Aug 2026.